
Cabaletta Bio, Inc.: shareholders and insiders
Price
$0.94
November 20, 2026Market cap $202M
What Ploutos Investor adds for Cabaletta Bio
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 27% since Nov 5, 2026, when the 10-Q these figures come from was filed ($1.28 then, $0.94 on Nov 20, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Jun 10, 2026, from their own Form 4 filings.
Bought on the market
$296.2K
8 people
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
- Jan 21, 2026Michael GerardGeneral CounselKind
- Jan 21, 2026Mark SimonKind
- Jan 21, 2026Steven NichtbergerPresident & CEOKind
- Jan 21, 2026Catherine BollardKind
- Jan 21, 2026Steve GavelChief Commercial OfficerKind
- Jan 21, 2026Shawn TomaselloKind
- Jan 21, 2026Gwendolyn BinderPresident, Science & Tech.Kind
- Jan 21, 2026David J. ChangChief Medical OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 21, 2026 | Michael GerardGeneral Counsel | 6,600 | $2.27 | $15.0K | Form 4 | |
| Jan 21, 2026 | Mark Simon | 11.1K | $2.28 | $25.2K | Form 4 | |
| Jan 21, 2026 | Steven NichtbergerPresident & CEO | 45.0K | $2.24 | $100.8K | Form 4 | |
| Jan 21, 2026 | Catherine Bollard | 4,405 | $2.27 | $10.0K | Form 4 | |
| Jan 21, 2026 | Steve GavelChief Commercial Officer | 22.2K | $2.27 | $50.3K | Form 4 | |
| Jan 21, 2026 | Shawn Tomasello | 22.7K | $2.21 | $50.2K | Form 4 | |
| Jan 21, 2026 | Gwendolyn BinderPresident, Science & Tech. | 11.3K | $2.19 | $24.8K | Form 4 | |
| Jan 21, 2026 | David J. ChangChief Medical Officer | 8,800 | $2.26 | $19.9K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 10, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by CABA's officers and directors from 2019 up to November 21, 2025, 7 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 2 more, back to 2019
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- T. Rowe Price Investment Management, Inc.Share of class13.1%
- Jennison Associates LLCShare of class11.4%
- Prudential FinancialShare of class11.4%
- Bain Capital Life Sciences Opportunities III, LPShare of class9.99%
- Adage Capital Management, L.P.with 2 more personsShare of class8.43%
- BlackRock, Inc.Share of class7.70%
- Cormorant Asset Management, LPwith 1 more personShare of class5.95%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13.1% | 28.14M | Nov 6, 20266 filings since Nov 7, 2025 | 13G/A | |
| Jennison Associates LLC | 11.4% | 24.27M | Jun 4, 20263 filings since Aug 6, 2025 | 13G/A | |
| Prudential Financial | 11.4% | 24.27M | Jun 5, 20263 filings since Aug 6, 2025 | 13G/A | |
| Bain Capital Life Sciences Opportunities III, LP | 9.99% | 17.24M | Aug 14, 20262 filings since Aug 14, 2025 | 13G/A | |
| Adage Capital Management, L.P.with 2 more persons | 8.43% | 14.17M | Aug 12, 20262 filings since Aug 12, 2025 | 13G/A | |
| BlackRock, Inc. | 7.70% | 13.01M | Oct 27, 20264 filings since Feb 5, 2025 | 13G/A | |
| Cormorant Asset Management, LPwith 1 more person | 5.95% | 10.00M | Aug 14, 20265 filings since Aug 14, 2025 | 13G/A |
Fell to 5% or less (7)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Norges Bank4.02%Nov 12, 202613G/A
- Vanguard Capital Management3.79%Oct 30, 202613G/A
- Millennium Management LLC1.30%Jul 23, 202613G/A
- Alyeska Investment Group, L.P.4.67%Feb 17, 202613G/A
- Citadel Advisors LLC3.40%Nov 14, 202513G/A
- Nichtberger Steven3.30%Aug 11, 202513G/A
- The Vanguard Group3.83%Jul 29, 202513G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter-23%
- Millennium Mgmt (Englander)In the quarter-69%
- D.E. ShawIn the quarter
- Renaissance TechnologiesIn the quarter-82%
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 78.7K | $200.0K | 0.00% | |
| Citadel Advisors (Griffin) | 2.71M | -23% | $5.2M | 0.00% |
| Millennium Mgmt (Englander) | 640.4K | -69% | $1.2M | 0.00% |
| D.E. Shaw | – | – | 0.00% | |
| Renaissance Technologies | 272.7K | -82% | $500.0K | 0.00% |
| AQR Capital | 80.8K | $200.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 18.2% of its shares outstanding were held short, +1.7% since the report before.
- Shares held short
- 39.29M
- 18.2%
- Since the report before38.61M on Sep 30, 2026
- +1.7%
- 7.2
- 5.44M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 79%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 6.28M
- Nov 15, 2023: Shares held short 5.06M
- Nov 30, 2023: Shares held short 5.67M
- Dec 15, 2023: Shares held short 5.63M
- Dec 29, 2023: Shares held short 6.22M
- Jan 12, 2024: Shares held short 6.42M
- Jan 31, 2024: Shares held short 6.39M
- Feb 15, 2024: Shares held short 6.83M
- Feb 29, 2024: Shares held short 7.01M
- Mar 15, 2024: Shares held short 7.09M
- Mar 28, 2024: Shares held short 8.50M
- Apr 15, 2024: Shares held short 9.87M
- Apr 30, 2024: Shares held short 10.25M
- May 15, 2024: Shares held short 9.10M
- May 31, 2024: Shares held short 9.47M
- Jun 14, 2024: Shares held short 9.45M
- Jun 28, 2024: Shares held short 7.18M
- Jul 15, 2024: Shares held short 7.51M
- Jul 31, 2024: Shares held short 8.77M
- Aug 15, 2024: Shares held short 6.28M
- Aug 30, 2024: Shares held short 6.39M
- Sep 13, 2024: Shares held short 6.39M
- Sep 30, 2024: Shares held short 5.32M
- Oct 15, 2024: Shares held short 3.78M
- Oct 31, 2024: Shares held short 3.71M
- Nov 15, 2024: Shares held short 3.60M
- Nov 29, 2024: Shares held short 4.50M
- Dec 13, 2024: Shares held short 6.22M
- Dec 31, 2024: Shares held short 6.02M
- Jan 15, 2025: Shares held short 6.45M
- Jan 31, 2025: Shares held short 6.25M
- Feb 14, 2025: Shares held short 6.20M
- Feb 28, 2025: Shares held short 6.76M
- Mar 14, 2025: Shares held short 6.23M
- Mar 31, 2025: Shares held short 6.13M
- Apr 15, 2025: Shares held short 5.80M
- Apr 30, 2025: Shares held short 6.10M
- May 15, 2025: Shares held short 5.52M
- May 30, 2025: Shares held short 6.20M
- Jun 13, 2025: Shares held short 6.47M
- Jun 30, 2025: Shares held short 5.61M
- Jul 15, 2025: Shares held short 6.54M
- Jul 31, 2025: Shares held short 6.03M
- Aug 15, 2025: Shares held short 6.31M
- Aug 29, 2025: Shares held short 5.82M
- Sep 15, 2025: Shares held short 5.57M
- Sep 30, 2025: Shares held short 6.04M
- Oct 15, 2025: Shares held short 11.22M
- Oct 31, 2025: Shares held short 12.95M
- Nov 14, 2025: Shares held short 16.20M
- Nov 28, 2025: Shares held short 18.11M
- Dec 15, 2025: Shares held short 18.95M
- Dec 31, 2025: Shares held short 18.80M
- Jan 15, 2026: Shares held short 18.44M
- Jan 30, 2026: Shares held short 18.68M
- Feb 13, 2026: Shares held short 18.63M
- Feb 27, 2026: Shares held short 18.64M
- Mar 13, 2026: Shares held short 19.04M
- Mar 31, 2026: Shares held short 19.97M
- Apr 15, 2026: Shares held short 19.64M
- Apr 30, 2026: Shares held short 20.63M
- May 15, 2026: Shares held short 22.84M
- May 29, 2026: Shares held short 22.94M
- Jun 15, 2026: Shares held short 26.24M
- Jun 30, 2026: Shares held short 34.06M
- Jul 15, 2026: Shares held short 41.01M
- Jul 31, 2026: Shares held short 40.78M
- Aug 14, 2026: Shares held short 42.80M
- Aug 31, 2026: Shares held short 41.44M
- Sep 15, 2026: Shares held short 33.33M
- Sep 30, 2026: Shares held short 38.61M
- Oct 15, 2026: Shares held short 39.29M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading56.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 56.5% of the shares in the reported trades were short sales, against 44.2% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 56.5%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 44.2%
- Change
- +12.3 pts
- Short sales a dayon average, of 2.28M shares
- 1.29M
- More than atof 3,666 US-listed companies, same days
- 72%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 39.1%
- Oct 15, 2026: Short sales 27.3%
- Oct 16, 2026: Short sales 33.7%
- Oct 19, 2026: Short sales 33.6%
- Oct 20, 2026: Short sales 52.4%
- Oct 21, 2026: Short sales 53%
- Oct 22, 2026: Short sales 45.7%
- Oct 23, 2026: Short sales 47.9%
- Oct 26, 2026: Short sales 51.9%
- Oct 27, 2026: Short sales 46.5%
- Oct 28, 2026: Short sales 46.2%
- Oct 29, 2026: Short sales 69.2%
- Oct 30, 2026: Short sales 54.5%
- Nov 2, 2026: Short sales 40.1%
- Nov 3, 2026: Short sales 57.9%
- Nov 4, 2026: Short sales 56.1%
- Nov 5, 2026: Short sales 38.1%
- Nov 6, 2026: Short sales 53.7%
- Nov 9, 2026: Short sales 51%
- Nov 10, 2026: Short sales 55.9%
- Nov 11, 2026: Short sales 55.7%
- Nov 12, 2026: Short sales 68.6%
- Nov 13, 2026: Short sales 55.5%
- Nov 16, 2026: Short sales 52.8%
- Nov 17, 2026: Short sales 71.4%
- Nov 18, 2026: Short sales 67.3%
- Nov 19, 2026: Short sales 65.9%
- Nov 20, 2026: Short sales 57.2%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Steven NichtbergerPresident & CEODirectly1.03M
- Mark SimonDirectorDirectly147.2K
- Gwendolyn BinderPresident, Science & Tech.Directly31.3K
- Shawn TomaselloDirectorDirectly–
- Steve GavelChief Commercial OfficerDirectly22.2K
- David J. ChangChief Medical OfficerDirectly8,800
- Michael GerardGeneral CounselDirectly6,600
- Catherine BollardDirectorDirectly5,405
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Steven NichtbergerPresident & CEO | 1.03M | – | Jan 21, 2026 | Form 4 |
| Mark SimonDirector | 147.2K | – | Jan 21, 2026 | Form 4 |
| Gwendolyn BinderPresident, Science & Tech. | 31.3K | – | Jan 21, 2026 | Form 4 |
| Shawn TomaselloDirector | – | 22.7K | Jan 21, 2026 | Form 4 |
| Steve GavelChief Commercial Officer | 22.2K | – | Jan 21, 2026 | Form 4 |
| David J. ChangChief Medical Officer | 8,800 | – | Jan 21, 2026 | Form 4 |
| Michael GerardGeneral Counsel | 6,600 | – | Jan 21, 2026 | Form 4 |
| Catherine BollardDirector | 5,405 | – | Jan 21, 2026 | Form 4 |
A lower bound: it counts only the 8 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.15%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.10%
- IWCiShares Micro-Cap ETFWeight in the fund0.08%
- IBBiShares Biotechnology ETFWeight in the fund0.03%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.01%
12 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 75
- Q4 2025: Managers 95
- Q1 2026: Managers 109
- Q2 2026: Managers 140
Institutional investors by quarter
The fund managers holding CABA, quarter by quarter, from Q4 2019 to Q2 2025, 23 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 140 managers held 159M shares, worth $493M. During the quarter 54 opened a position, 24 closed one, 48 added and 20 trimmed.
The largest holders, Q2 2026
- Jennison AssociatesIn the quarter+123%
- T. Rowe Price Investment ManagementIn the quarter+70%
- Bain Capital Life Sciences InvestorsIn the quarter+78%
- BlackRockIn the quarter+353%
- Adage Capital Partners GpIn the quarter+3.9%
- State StreetIn the quarter×16.7
- Vanguard Capital ManagementIn the quarter+79%
- Cormorant Asset ManagementIn the quarter-9.1%
- Price T Rowe AssociatesIn the quarter+899%
- Woodline PartnersIn the quarter+236%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Jennison Associates | 20.03M | +123% | $62M |
| T. Rowe Price Investment Management | 18.87M | +70% | $59M |
| Bain Capital Life Sciences Investors | 17.24M | +78% | $54M |
| BlackRock | 10.75M | +353% | $33M |
| Adage Capital Partners Gp | 9.17M | +3.9% | $29M |
| State Street | 7.84M | ×16.7 | $24M |
| Vanguard Capital Management | 7.23M | +79% | $22M |
| Cormorant Asset Management | 5.00M | -9.1% | $16M |
| Price T Rowe Associates | 4.42M | +899% | $14M |
| Woodline Partners | 4.20M | +236% | $13M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Cabaletta Bio's filings show?
Who buys and sells is one part of Cabaletta Bio's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have CABA's insiders bought or sold?
From Jun 10, 2026 to Jun 10, 2026 Cabaletta Bio's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold CABA?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $5.2M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.